- Conditions
- Lung Cancer
- Interventions
- docetaxel, vinorelbine tartrate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- TAK-988, TAK-988 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Glendale, California • Millcreek, Utah
- Conditions
- Parkinson Disease
- Interventions
- Postural perturbation
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Salt Lake City, Utah
- Conditions
- Influenza Immunization
- Interventions
- Pandemic flu H5 mRNA vaccine, Placebo
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
- Conditions
- Prostate Cancer
- Interventions
- Clinical Order Check, Academic Detailing, Audit and Feedback
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Palo Alto, California • West Los Angeles, California • West Haven, Connecticut + 8 more
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Centanafadine Hydrochloride
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 84
- States / cities
- Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, etoposide, ifosfamide
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Endometriosis
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 60
- States / cities
- Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
- Conditions
- Lung Cancer
- Interventions
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody GD2 anti-idiotype vaccine, cisplatin, etoposide, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 99
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Sudden Cardiac Death
- Interventions
- Arm 1 (ATP+Shock), Arm 2 (shock only)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 2,692 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 89
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
- Conditions
- Heart Diseases, Aortic Stenosis, Severe
- Interventions
- Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Durvalumab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 993
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more
- Conditions
- Type 2 Diabetes, Cortisol Excess
- Interventions
- clofutriben, Placebo
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 53 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Afferent block
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Myelofibrosis (MF)
- Interventions
- Placebo for Navitoclax, Ruxolitinib, Navitoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 35
- States / cities
- Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Paclitaxel, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 431
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 298 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 117
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Knee-extensor exercise test, Exercise test with restricting/releasing blood flow, Exercise test with variable oxygen concentration and MRI, Exercise test with oral antioxidant or placebo cocktail
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Drug
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 58
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 37 more
- Conditions
- Colorectal Cancer
- Interventions
- irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 430
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Ulcerative Colitis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 944 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 75
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 42 more
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 752
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more